Compare ATLX & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATLX | PRQR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | Brazil | Netherlands |
| Employees | 64 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 166.5M |
| IPO Year | 2012 | 2014 |
| Metric | ATLX | PRQR |
|---|---|---|
| Price | $4.22 | $1.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $7.25 |
| AVG Volume (30 Days) | ★ 1.0M | 497.0K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,491.00 | N/A |
| Revenue This Year | $64,564.67 | N/A |
| Revenue Next Year | $785.59 | $13.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.60 | $1.33 |
| 52 Week High | $8.25 | $3.10 |
| Indicator | ATLX | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 40.41 | 50.62 |
| Support Level | $3.97 | $1.37 |
| Resistance Level | $5.12 | $1.76 |
| Average True Range (ATR) | 0.35 | 0.10 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 6.91 | 60.61 |
Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.